News and Trends 4 Apr 2023 BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets… April 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2022 Tubulis Rides Investment Wave in ADCs with €60M Series B …drug-to-antibody ratio as well as the linker chemistry of the ADC,” said Schumacher. For example, ADCs with very toxic payloads should pack fewer molecules per antibody, whereas candidates with milder… May 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Hummingbird Bioscience and Synaffix to develop ADC program Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix… January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2017 Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis …series of phase III trials with the antibody for psoriatic arthritis, as well as another head-to-head study with the anti-IL-17 antibody, Cosentyx. Boehringer Ingelheim and AbbVie have partnered to develop… October 17, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
In Depth 2 Apr 2025 Beyond amyloid: The search for the next big thing in Alzheimer’s treatment …the amyloid-plaques-targeting antibody showed some plaque clearance, the cognitive data were mixed at best. Then came Leqembi in 2023. This second-generation amyloid-targeting antibody showed a modest but statistically significant slowing… April 2, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Aug 2025 The Sanofi pipeline in 2025: Is the play-to-win strategy working? …Sanofi acquires the full Vigil pre-clinical neurodegenerative pipeline. However, the TREM2 agonist antibody iluzanebart (VGL101), which Vigil had been developing for rare microgliopathies, was excluded from the acquisition, and rights… August 22, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 9 Aug 2023 Meet the startup working to help treat a rare pediatric cancer …– a central process in the immune system – thereby minimizing pain caused by the antibody binding to peripheral nerves. This, in turn, enables higher antibody dosing. To add to… August 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2017 Hopes are up: A Second Phase III Trial for Alzheimer’s Disease …returned encouraging data. Biogen’s antibody candidate aducanumab also targets Aβ aggregation and is also currently being evaluated in two large-scale Phase III trials. Even with the recent disappointing results of… February 28, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2024 German biotech raises $150M on its way to tackle cancer therapy resistance …Gilde Healthcare. CatalYm is a Munich-based biotech company, with a novel approach to tackle cancer resistance through its lead candidate, visugromab. This humanized monoclonal antibody targets the tumor-produced growth differentiation… July 16, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 16 Nov 2017 Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics …of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates to control the immune system,… November 16, 2017 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2024 Six immunology biotech companies revolutionizing immune treatments in 2024 …mast cells. This candidate will be trialed to treat chronic inducible urticaria. Meanwhile, the company’s second candidate is called SAB03, which agonizes PD-1, a clinically validated target in rheumatoid arthritis,… September 19, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? …antibody targeting PD-L1 and VEGF-A had a 69.7% overall survival rate at 18 months. While the drug overtook Keytruda in the clinic, the question remains of whether the candidate will… January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email